Oncternal Therapeutics has joined the growing ranks of San Diego biotechs to go public, but it didn’t go through an IPO to get there.
The San Diego-based company said Monday that it completed a reverse merger with GTx, a Memphis, TN biotech whose market value plummeted last fall after its lead drug candidate failed a Phase 2 trial.
GTx had been testing a therapy for post-menopausal women with stress urinary incontinence, a condition that can cause a person to unintentionally lose urine during physical activity. But the experimental drug, a selective androgen receptor modulator called enobosarm that aimed to limit how… Read more »
UNDERWRITERS AND PARTNERS